RxDoctor Payments Data

Ashley Berniard, PA

Physician Assistant · Kingwood, TXNPI 1235406448

Payments from drug & device makers

$5,975in general payments, 2019–2025

Across 325 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$801
  • Novo Nordisk$631
  • GSK$446
  • Lilly USA, LLC$418
  • AstraZeneca$333
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$275
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$5,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,975 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$7,119
Medicare patients
58
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$136,237
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$52,962
XareltoRivaroxaban22$31,516
EliquisApixaban21$25,995
FarxigaDapagliflozin Propanediol17$23,770
VascepaIcosapent Ethyl26$22,298
Tresiba Flextouch U-200Insulin Degludec40$21,880
JanuviaSitagliptin Phosphate15$19,649
MounjaroTirzepatide15$19,022
RexultiBrexpiprazole14$18,608
JardianceEmpagliflozin11$13,488
Breo ElliptaFluticasone/Vilanterol23$12,994
Tresiba Flextouch U-100Insulin Degludec21$12,481
LivaloPitavastatin Calcium11$8,129
AbrysvoRsv Vacc, Pref A And Pref B/Pf20$6,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$631$136,23790 claims
GSKTrelegy Ellipta, Breo Ellipta$446$65,95677 claims
PfizerEliquis, Abrysvo$27$32,35441 claims
Johnson & JohnsonXarelto$104$31,51622 claims
AstraZenecaFarxiga$333$23,77017 claims
MerckJanuvia$30$19,64915 claims
Lilly USA, LLCMounjaro$418$19,02215 claims
Otsuka America Pharmaceutical, Inc.Rexulti$216$18,60814 claims
Boehringer IngelheimJardiance$95$13,48811 claims
Kowa Pharmaceuticals America, Inc.Livalo$31$8,12911 claims
AbbVieSynthroid$801$75317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →